Alternative therapy with ivabradine in patients with functional class III chronic heart failure

Kardiologiya

Volumn 51, Issue 8, 2011, Pages 39-44

  Kanorskiy, S G ^a   Tregubov, V G ^a   Pokrovskiy, V M ^a  

^a KUBAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cardio respiratory synchronism; Chronic heart failure; Ivabradine; Metoprolol succinate; Regulatory adaptive status

Indexed keywords

BENZAZEPINE DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; IVABRADINE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG MONITORING; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BENZAZEPINES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DRUG MONITORING; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80555156670     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
2. Jessup M., Abraham W. T., Casey D. E. et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:1343-1382.
3. Tavazzi L., Maggioni A. P., Marchioli R. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISS1-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-1230.
4. Moss A. J. What we have learned from the family of multicenter automatic defibrillator implantation trials. Circ J 2010;74:1038-1041.
5. Dickstein K., Vardas P. E., Auricchio A. et al. 2010 Focused Update of ESC guidelines on device therapy in heart failure. An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur. Heart J. doi: 10.1093/eurheartj/ehq337.
6. Fox K., Ford I., Steg P. G. et al. On the BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular sistolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
7. Bohm M., Swedberg K, Komajda M. et al. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-894.
8. Di Francesco D., Camm A. J. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004;64:1757-1765.
9. Cooney M. T., Vartialnen E., Laakitaien T. et al. Elevaited resing heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 2010;159:612-619.
10. Cucheral M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a metaregression of randomized clinical trials. Eur Heart J 2007;28:3012-3019.
11. McAlister FA., Wiebe N., Ezekowitz J. A. et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-794.
12. Lopez-Sendon J., Swedberg K., McMurray J. et al. Expert consensus document on B-adrenergic receptor bickers. The Task force on betablockers of the European Society of Cardiology. Eur Heart J 2004;25:1341-1362.
13. Heusch G., Schulz R. The role of heart rate and the benefits of heart rate reduction in acute myocardial ishemia. Eur Heart J 2007; Suppl. F: 8-14.
14. De Ferrari G. M., Mazzuero A., Agntsina L. et al. Ivabradine infusion in patiens with severe heart failure is safe, reduces heart rate and increases left ventricular stroke volume and systolic work. Eur Heart J 2006;27 Abstract Suppl.330.
15. Mulder P., Barbier S., Chagraoui A. et al. Long-term heart rate reduction induced by the selection and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-1679.
16. Savelieva I., Camm A. J. If inhibition with ivabradine: electrophysiological effects and safety. Drugs Saf 2008;31:95-107.
17. Couvreur N., Tissier R., Pons S. et al. Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression. Eur Heart J 2010;31:1529-1537.
18. Zhang R. L., Christensen L. P., Tomanek R. J. Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction. Anat Rec (Hoboken) 2010;293:839-848.
19. Swedberg K., Komajda M., Böhm M. et al. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I (f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75-81.
20. Swedberg K., Komajda M., Böhm M. et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet 2010;376:875-885.
21. Sette A., Martino A., Lioy E., Calo L. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction. J Cardiovasc Electrophysiol 2010;21:815-817.
22. Zwicker C., Becker M., Upper W. et al. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine. Cardiology 2010;116:174-177.